Every clinician remembers the first time they realized the textbook was lying to them about time. You are standing in an exam room, looking at two German Shepherds. Both are precisely eight years old according to their microchips. But the first dog moves with a fluid, springy elasticity, its eyes bright, its metabolic profile as clean as a two-year-old’s. The second dog is heavy, dull-eyed, stiffening in the hindquarters, its bloodwork showing a slow, sub-clinical smoldering of inflammation that has no distinct diagnostic name. The calendar says they are identical. The biology says they are living in two entirely different decades. For generations, medicine treated aging like an external force—a slow accumulation of mileage, like dust gathering on a shelf or rust eating away at an old truck frame. We assumed that time was the variable doing the damage. But as we dive deeper into the comparative biology of companion dogs, that model is breaking down. Aging is not an accumulation of external years. It is an internal tempo. It is a highly active, coordinated, and ultimately measurable biological drift. To understand this drift, it helps to stop thinking of the body as a machine that simply wears out, and start thinking of it as an orchestra whose musicians are slowly losing their shared metronome. When the metronome is crisp, every cellular process is tightly synchronized. Protein synthesis matches protein degradation. The immune system deploys sharp, targeted responses to pathogens and then completely turns off. Mitochondria produce clean energy without drowning the cell in reactive oxygen species. As the internal metronome drifts, the synchronization fails. This isn't necessarily a state of overt disease—not yet. It is a subtle shift in the operational background noise of the body. We see this clearly when we look at the shifting ratios of cell populations, like the balance between helper and cytotoxic T-cells, the CD4/CD8 ratio. In youth, this ratio reflects an immune system that is poised, adaptive, and highly communicative. As the metronome slows down, the ratio skews, signaling an immune system that is becoming simultaneously exhausted and hyper-reactive. It is the molecular equivalent of a construction crew that has stopped building new structures but refuses to stop running their heavy machinery all night, filling the neighborhood with noise and exhaust. The field calls this inflammaging. It isn’t an infection; it is a breakdown in systemic coordination.

The idea that “BPC-157 feeds cancer” sounds convincing at first because it leans on a real biological truth, but then stretches that truth past where the evidence actually goes. To understand what is really happening, you have to zoom out and look at how the body makes decisions at the cellular level. Cells are not blindly following one signal. They are constantly integrating multiple inputs, like a control center weighing oxygen levels, damage signals, inflammation, energy status, and structural integrity. BPC-157 seems to operate inside that decision-making network, not as a simple on/off switch for growth. Let’s start with the fear itself. VEGF is a real molecule with a real job. It stands for vascular endothelial growth factor, and its role is to help build blood vessels. If tissue is injured or deprived of oxygen, VEGF helps recruit new blood supply. Tumors can hijack this system. They release VEGF to grow their own blood supply, which helps them expand. That part is not controversial. The mistake happens when people assume that anything touching VEGF automatically behaves like VEGF. That is like assuming that anyone who walks into a construction site is a construction worker. Some people are there to build. Others are there to supervise, clean up, or shut things down. BPC-157 looks much more like a coordinator than a builder. At a molecular level, true angiogenic drivers like VEGF-A, FGF-2, or PDGF act as primary signals. They bind directly to receptors like VEGFR2 and initiate a cascade that pushes endothelial cells to proliferate, migrate, and form new vessel structures. This involves pathways like MAPK/ERK for proliferation, PI3K/Akt for survival, and eNOS activation for nitric oxide production and vessel dilation. When these signals are sustained, you get continuous vessel growth. That is exactly what tumors exploit. BPC-157 does not appear to behave like that. In resting endothelial cells, meaning cells that are not experiencing injury or stress, BPC-157 does not trigger angiogenesis. No tube formation, no forced proliferation, no “build vessels now” signal. That alone separates it from classic tumor-supporting growth factors.

@Anthony Castore what are your thoughts of TND1128 being superior over NMN as a NAD+ precursor? The studies I’ve read indicate that TND1128 is a superior MAM+ precursor for activating SIRTUINS, help self regulate redox, with anti antioxidant and anti-inflammatory properties. That being said, all the studies were conducted on mice and we know that there’s not a direct correlation.

I thought this might be right up your alley to discuss @Anthony Castore . I am seeing the topic pick up again about why you should avoid BPC/TB due to possible increase in cancer likelihood. I can't tell if this is all just fear mongering or not. There doesn't appear to be any evidence regarding this outside of referencing a mouse study that was done: ---------------------------------------------------------------------------------------------------------------------------------------------------------- "In most solid tumors studied in mice, including fibrosarcoma, melanoma, non-small cell lung cancer (NSCLC), colon cancer, and glioblastoma, TB4 overexpression promotes tumor growth, metastasis, and angiogenesis." ----------------------------------------------------------------------------------------------------------------------------------------------------------- One person is stating that since BPC up-regulates VEGF, this would be a pathway towards cancer development (below is what they posted). ----------------------------------------------------------------------------------------------------------------------------------------------- VEGF is historically a promoting factor in oncological aspects rather than causative, but this isn't the only concern. VEGF was originally named "vascular permeability factor" for a reason. It opens gaps between endothelial cells, letting plasma proteins and fluid leak into the interstitial space. Off-target stimulation means edema in tissues that don't need increased perfusion. The problem is that VEGF receptors sit on endothelial cells throughout the entire body, not just in the tissue you're trying to help. So if VEGF reaches non-target tissues, several things go wrong. It can produce off-target angiogenesis, meaning new blood vessel growth where you do not want it. That can produce abnormal, fragile, leaky vessels rather than healthy functional ones. VEGF also increases vascular permeability, so tissue can become swollen or edematous. PMID: 35969170, 20400620

Has anyone here used ARA290?